Latest Operational Management News

Synertec has secured a pivotal contract to supply its zero-emission Powerhouse system to Shell QGC’s Coal Seam Gas operations in Queensland, marking a significant step in industrial decarbonisation.

Solvar Limited has sold its New Zealand arrears loan book for NZ$8 million, accelerating its exit from the NZ market and announcing a special fully franked dividend for shareholders.

Bubs Australia Limited reported a solid FY25 with $102.5 million revenue and outlined ambitious FY26 guidance targeting up to $125 million, driven by overseas markets and strategic investments.

Dalrymple Bay Infrastructure Limited has reaffirmed its position as the world’s largest metallurgical coal export facility with full contracted capacity through 2028 and unveiled detailed plans for a significant terminal expansion.

AVADA Group reported a 10.5% revenue decline in FY2025 amid operational consolidation and leadership changes, while conducting a strategic review of its New Zealand operations. Despite setbacks, the company remains cautiously optimistic about future growth.

GoldArc Resources has taken a decisive step in advancing its Mt Stirling Project by securing 90% ownership and full operational control, removing the need for a feasibility study before mining decisions.

Monash IVF Group has appointed Dr Victoria Atkinson as its new Managing Director and CEO, effective May 2026, signaling a strategic leadership shift for the assisted reproductive services provider.

ANZ Group Holdings reported a 10% decline in cash profit for FY2025 despite an 8% rise in operating income, maintaining its dividend amid significant restructuring and regulatory costs.

Bellavista Resources has appointed former De Grey Mining executives Glenn Jardine and Peter Canterbury as Managing Director and Finance Director, aiming to leverage their proven track records to accelerate exploration and development.

De.mem Limited has completed its $3 million acquisition of Core Chemicals, a specialty chemical supplier to Western Australia's gold mining sector, significantly expanding its market footprint and boosting pro-forma EBITDA to $1.6 million.

Chimeric Therapeutics has progressed its CHM CDH17 and CHM CORE-NK clinical trials with promising safety and efficacy signals, while securing a key manufacturing partnership and appointing a renowned haematologist to its board. However, the company faces a pressing cash runway challenge.

Key Petroleum Limited is on the cusp of securing critical government approvals for its Queensland projects, bolstered by new major shareholders and strategic board changes that set the stage for accelerated development and diversification.